JNJ-64041809

Listeria monocytogenes-based live attenuated immunotherapy · Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JNJ-64041809, covering 2016-11-22 to 2025-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 1]

See pricing